Why are AbbVie shares down 2% today?

Traders Union
All News
Stocks
Abbvie slides 2.03% today after FDA news

Highlights

AbbVie received two Breakthrough Therapy Designations for telisotuzumab adizutecan and reported positive Phase 3 results for epcoritamab in DLBCL.
AbbVie delivered Q2 2026 revenue of $16.99 billion, a 10.2% increase, and declared a $1.73 per share dividend.
Shares of AbbVie trade in a bullish medium- to long-term trend near $265.85, with an expected five-day range of $257.53 to $274.17 and near-term overbought signals increasing pullback risk.

Positive trial results and approvals counteracted by ongoing selling pressure

AbbVie was granted two Breakthrough Therapy Designations from the U.S. FDA for telisotuzumab adizutecan in colorectal cancer and non-small cell lung cancer. The company and Genmab reported positive topline Phase 3 results for the EPCORE DLBCL-2 trial, showing a 51% reduction in risk of disease progression or death with epcoritamab plus R-CHOP compared to standard therapy. AbbVie reported Q2 2026 revenue of $16.99 billion, up 10.2% year-over-year, and declared a quarterly dividend of $1.73 per share. Recent approvals include FDA clearance of Juvmo for Parkinson’s disease and European Commission approval for Rinvoq in juvenile idiopathic arthritis, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees a disconnect between AbbVie’s positive headlines and its weak price action. He notes that despite regulatory wins and solid Q2 numbers, the recent selloff after a downside gap is concerning. Technical signals are overextended, with most indicators warning of overbought conditions near $263.46. While support aligns with moving averages, Kharitonov remains skeptical given heightened risk of a correction and persistent broader selling. "Aggressive buying at these levels is risky — traders should tighten stops and watch for potential invalidation if $263.46 fails."

Viktoras Karapetjanc, expert at Traders Union, believes AbbVie’s outlook is reinforced by recent breakthroughs and robust earnings growth. He emphasizes that double Breakthrough Therapy Designations and positive trial data highlight long-term value. The bullish technical structure remains intact, with prices holding above all major moving averages. Karapetjanc sees further growth likely as the market digests short-term volatility and recent support holds. "I expect continued upside and believe AbbVie’s pipeline and regulatory progress offer multiple setups for bullish investors."

Parshwa Turakhiya, analyst, notes mixed sentiment for AbbVie as bullish momentum collides with overbought technicals. Intraday volatility remains constrained, suggesting traders are cautious after the gap-down. He highlights immediate levels at $263.46 and $270.7 as key triggers for short-term setups. "If bulls reclaim control above $270.7, a fresh momentum push could emerge — but tight stops are essential in this crowded market."

Overbought risks rise as bullish momentum faces immediate weakness

AbbVie is trading above the 20-day ($263.46), 50-day ($258.32), and 200-day ($232.18) moving averages, indicating sustained bullish momentum across all timeframes. The Ichimoku Kijun at $261.17 provides nearby support, with a bullish medium- to long-term trend structure reinforced by the positive MA-50 vs MA-200 alignment. The next ceiling is at $270.7 and the floor at $263.46. Momentum signals present a divided short-term picture: MACD and RSI both support further upside, but with RSI at 65.22 and the Stochastic RSI and Commodity Channel Index in the overbought zone, risk of a pullback has grown. Bull/Bear Power at 10.33 confirms buyers still dominate intraday momentum and also flags overbought conditions. Price is near today’s low, with intraday volatility at 0.30%, reflecting immediate pressure after a weak open that aligns with overbought signals.

Earlier, analysts noted that AbbVie’s sustained bullish momentum was supported by a series of positive clinical and regulatory developments. The current outlook substantiates this view with continued strength across major moving averages, but with overbought signals intensifying, traders should monitor the $270.7 ceiling as a potential inflection point for near-term price action.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.